Abstract
Pituitary tumor-transforming gene (pttg) is a distinct proto-oncogene which is expressed in certain normal tissues with high proliferation rate and in a variety of tumors. PTTG is the vertebrate analog of yeast securins Pds1 and Cut2 with a key role in the regulation of sister chromatid separation during mitosis. Impairment of PTTG regulated functions is expected to lead to chromosomal instability and aneuploidy. Human pttg (hpttg) is abundantly expressed in Jurkat T lymphoblastic lymphoma cells but not in normal peripheral blood leukocytes. To obtain additional data on the potential role of hpttg in lymphomagenesis we selected 150 cases of lymphoid tumors for the assessment of hpttg expression in tumor tissues. Immunohistochemical studies on formalin-fixed, paraffin-embedded tissues revealed hPTTG in 38.8% of B-cell lymphomas, 70.2% of T-cell lymphomas, and 73.1% of Hodgkin's lymphomas. Among B-cell lymphomas, the most frequently immunostained tumors were plasma cell tumors, diffuse large cell lymphomas, and follicle center cell lymphomas. In Hodgkin's disease, immunoreactivity was mainly noted in Reed-Sternberg cells. In conclusion, the frequent overexpression of hpttg in many histological subtypes of lymphoma suggests the involvement of this proto-oncogene in lymphomagenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B . 1998 Nature 392: 300–303
Chien W, Pei L . 2000 J. Biol. Chem. 275: 19422–19427
Cohen-Fix O, Koshland D . 1997 Proc. Natl. Acad. Sci. USA. 94: 14361–14366
Cory S . 1986 Adv. Cancer Res. 47: 189–234
Dasika GK, Lin SCJ, Zhao S, Sung P, Tomkinson A, Lee EYHP . 1999 Oncogene 18: 7883–7899
Davies J, Badiani P, Weston K . 1999 Oncogene 18: 3643–3647
Domínguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M, Pintor-Toro JA . 1998 Oncogene 17: 2187–2193
Hardwick KG . 1998 Trends Genet. 14: 1–4
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA . 1994 Blood 84: 1361–1392
Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S . 2000 Lancet 355: 716–719
Hecht JL, Aster JC . 2000 J. Clin. Oncol. 18: 3707–3721
Jallepalli PV, Waizenegger IC, Bunz F, Langer S, Speicher MR, Peters JM, Kinzler KW, Vogelstein B, Lengauer C . 2001 Cell 105: 445–457
Jin S, Weaver DT . 1997 EMBO J. 16: 6874–6885
King RW, Glotzer M, Kirschner MW . 1996 Mol. Biol. Cell. 7: 1343–1357
Landanyi M, Offit K, Jhanwar SC, Filippa DA, Chaganti RSK . 1991 Blood 77: 1057–1063
Lengauer C, Kinzler KW, Vogelstein B . 1998 Nature 396: 643–649
Li GC, Ouyang H, Li X, Nagasawa H, Little JB, Chen DJ, Ling CC, Fuks Z, Cordon-Cardo C . 1998 Mol. Cell. 2: 1–8
Marcu KB, Bossone SA, Patel AJ . 1992 Annu. Rev. Biochem. 61: 809–860
Pei L . 2001 J. Biol. Chem. 276: 8484–8491
Pei L, Melmed S . 1997 Mol. Endocrinol. 11: 433–441
Rabbits TH . 1994 Nature 372: 143–149
Ramos-Morales F, Domínguez A, Romero F, Luna R, Multon MC, Pintor-Toro JA, Tortolero M . 2000 Oncogene 19: 403–409
Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, Popplewell L, Offit K, Jhanwar SC, Chaganti RS . 1998 Blood 92: 234–240
Romero F, Multon MC, Ramos-Morales F, Domínguez A, Bernal JA, Pintor-Toro JA, Tortolero M . 2001 Nucleic Acids Res. 29: 1300–1307
Sáez C, Japón MA, Ramos-Morales F, Romero F, Segura DI, Tortolero M, Pintor-Toro JA . 1999 Oncogene 18: 5473–5476
Strausberg RL, Dahl CA, Klausner RD . 1997 Nat. Genet. 15: 415–416
Werner CA, Döhner H, Joos S, Trümper LH, Baudis M, Barth TFE, Ott G, Möller P, Lichter P, Bentz M . 1997 Am. J. Pathol. 151: 335–342
Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S . 1999a J. Clin. Endocrinol. Metab. 84: 761–767
Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, Melmed S . 1999b Mol. Endocrinol. 13: 156–166
Zou H, McGarry TJ, Bernal T, Kirschner MW . 1999 Science 285: 418–422
Acknowledgements
This work has been supported by grants from Ministerio de Educación y Cultura, Spain (SAF99-0125-C03); Dirección General de Universidades e Investigación, Junta de Andalucía; and Fundación Andex.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sáez, C., Pereda, T., Borrero, J. et al. Expression of hpttg proto-oncogene in lymphoid neoplasias. Oncogene 21, 8173–8177 (2002). https://doi.org/10.1038/sj.onc.1205954
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205954
Keywords
This article is cited by
-
PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma
Journal of Hematology & Oncology (2015)
-
The pituitary tumor transforming gene 1 (PTTG-1): An immunological target for multiple myeloma
Journal of Translational Medicine (2008)
-
Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma
Modern Pathology (2006)
-
Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells
Oncogene (2005)
-
Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells
Oncogene (2005)